QuoTrend
DashboardScreenCompareStrategiesPortfolioSectorsHeatmapsInsiderFuturesForexCryptoCalendarNews
DashboardScreenCompareStrategiesPortfolioSectorsHeatmapsInsiderFuturesForexCryptoCalendarNewsMore
⌘K
Help
QuoTrend
PAGEHome
HomePricingContactHelpTermsPrivacy
Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
© 2026 QuoTrend
Screen

VCEL

QT69Vericel Corporation
NASDAQ·Healthcare·Biotechnology·USA
Latest market price
40.10
+0.97+2.48%
OverviewShort InterestFilings
VCELQT69Vericel Corporation·NASDAQ
OverviewShort InterestFilings
40.10+2.48%
TA
Loading chart...
Screen all →
VRTX-1.60%$451.63REGN+0.33%$609.94ARGX-1.63%$877.72ALNY-1.64%$278.09RVMD+3.31%$162.99MRNA+3.50%$63.96UTHR-2.70%$536.59BNTX-1.44%$90.89
Snapshot
Index-P/E92.57EPS (ttm)
0.42
Insider Own1.83%
Shs Outstand51.07M
Perf Week3.97%
Market Cap2.00BForward P/E45.75EPS next Y0.88Insider Trans0.70%Shs Float-Perf Month16.27%
Enterprise Value1.98BPEG0.14EPS next Q-0.04Inst Own-Short Float-Perf Quarter22.48%
Income21.58MP/S6.84EPS this Y12.41%Inst Trans-Short Ratio-Perf Half Y12.96%
Sales292.08MP/B5.58EPS next Y85.64%ROA4.42%Short Interest-Perf YTD11.36%
Book/sh6.97P/C32.20EPS next 5Y47.91%ROE6.41%52W High43.57 -7.96%Perf Year-3.37%
Cash/sh2.84P/FCF34.57EPS past 3/5Y-ROIC3.35%52W Low28.95 38.51%Perf 3Y-
Dividend Est.-EV/EBITDA56.25Sales past 3/5Y18.95% 17.35%Gross Margin74.84%Volatility2.44% 3.02%Perf 5Y-
Dividend TTM-EV/Sales6.79EPS Y/Y TTM110.00%Oper. Margin5.40%ATR (14)1.63Perf 10Y-
Dividend Ex-Date-Quick Ratio4.79Sales Y/Y TTM23.21%Profit Margin7.35%RSI (14)69.44Recom2.36
Dividend Gr. 3/5Y-Current Ratio5.18EPS Q/Q47.83%SMA2010.95%Beta1.27Target Price52.67
Payout0.00%Debt/Eq0.27Sales Q/Q28.30%SMA5013.72%Rel Volume2.73Prev Close39.13
Employees357LT Debt/Eq0.24EarningsJul 30SMA20013.15%Avg Volume616.58KPrice40.10
IPO DateFeb 04, 1997Option/ShortYes / YesEPS/Sales Surpr.20.00% 6.25%Net Debt/EBITDA-0.42Volume1,686,286Change2.48%
Analyst Ratings
DateActionAnalystRatingTarget
May-08-26ReiteratedH.C. WainwrightBuy$64 → $70
Apr-15-26ReiteratedTruist Financial$48 → $42
Mar-10-26ReiteratedLeerink Partners$46
Dec-18-25ReiteratedTruist Financial$50 → $45
Oct-15-25ReiteratedTruist Financial$46 → $41
Sep-17-25DowngradeBTIGBuy → Neutral
Dec-18-24ReiteratedTruist Financial$61 → $67
Aug-26-24ReiteratedBTIGBuy$56 → $55
Aug-02-24ReiteratedH.C. WainwrightBuy$55 → $60
Jul-16-24ReiteratedTruist Financial$56 → $57
Latest News
Jun-16-26
Jun-16-2608:10AM
Vericel Corp (NASDAQ:VCEL): Growth and Technical Setup Align for Potential BreakoutChartMill
Company
Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements
DataTimeframe
Line Item (USD, M)
TTM
—
FY 2025
12/31/2025
FY 2024
12/31/2024
FY 2023
12/31/2023
FY 2022
12/31/2022
FY 2021
12/31/2021
FY 2020
12/31/2020
FY 2019
12/31/2019
FY 2018
12/31/2018
Total Revenue292276237
Upgrade your experience to unlock full historical data
Cost of Goods Sold Incl. D&A747165
Gross Profit219206172
Selling, General and Administrative Excl. Other174167143
Research and Development282825
Other Operating Expense100
Operating Income15115
Interest Expense021
Unusual Expense
———
Non-Operating Income (Expense)-8-8-7
Net Income Before Taxes221711
Income Taxes110
Consolidated Net Income211710
Net Income From Continuing Operations211710
Net Income211710
EPS (Recurring)0.430.330.21
EPS (Basic, Before Extraordinaries)0.430.330.21
EPS (Diluted)0.420.320.20
EBITDA353017
Other After Tax Adjustments
———
Stock Option Compensation Expense
———
Price To Earnings Ratio95.48112.53—
Price To Sales Ratio7.006.65—
Gross Margin75.0074.6472.57
Operating Margin5.143.992.11
Net Margin7.196.164.22
Shares Outstanding515149
Market Capitalization2,0451,837—
Operating Lease Expense
———
Insider Trading Volume
$45.75$41.85$37.95$34.04$30.14● Close Price0.00M0.40M0.80M1.20M1.60MUSD Trades VolumeJunJulAugSepOctNovDec2026FebMarAprMayJun
Insider Trading
InsiderRelationshipDateTransactionCost#SharesValue ($)#Shares TotalSEC Form 4
Hopper Jonathan MarkChief Medical OfficerJun 02 '26Option Exercise16.668,750145,77680,128Jun 04 12:00 AM
Hopper Jonathan MarkChief Medical OfficerJun 02 '26Sale35.004,375153,12575,753Jun 04 12:00 AM
MCLAUGHLIN KEVIN FDirectorMay 13 '26Option Exercise7.8414,000109,76021,800May 15 12:00 AM
MCLAUGHLIN KEVIN FDirectorMay 13 '26Sale32.837,000229,77518,300May 15 12:00 AM
Wotton Paul KDirectorMay 11 '26Sale32.7410,000327,42518,802May 13 12:00 AM
SIEGAL JONATHANPrincipal Accounting OfficerMay 07 '26Sale40.501,42257,5911,118May 08 12:00 AM
Mara Joseph Anthony JrChief Financial OfficerMay 07 '26Sale40.505,000202,50021,009May 08 12:00 AM
SIEGAL JONATHANPrincipal Accounting OfficerMay 06 '26Sale38.003,433130,4542,540May 08 12:00 AM
Wotton Paul KDirectorApr 29 '26Option Exercise0.006,400028,802May 01 12:00 AM
WRIGHT LISADirectorApr 29 '26Option Exercise0.006,400015,851May 01 12:00 AM
ZERBE ROBERT L MDDirectorApr 29 '26Option Exercise0.006,400032,995May 01 12:00 AM
MCLAUGHLIN KEVIN FDirectorApr 29 '26Option Exercise0.006,400018,300May 01 12:00 AM
Rubino Alan LDirectorApr 29 '26Option Exercise0.006,400064,194May 01 12:00 AM
Hagen HeidiDirectorApr 29 '26Option Exercise0.006,400035,050May 01 12:00 AM
Hopper Jonathan MarkChief Medical OfficerApr 02 '26Option Exercise10.956,94476,03679,028Apr 06 12:00 AM
open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR